Skip to main content
SpringerLink
Log in

Traitements systémiques des cancers du sein métastatiques

  • Chapter
Thérapeutique du cancer

  • 769 Accesses

Résumé

Les patientes présentant un cancer métastatique demeurent dans une situation incurable mais pour laquelle les progrès thérapeutiques ont permis d’améliorer considérablement à la fois la qualité de vie et le pronostic. Bénéfice acquis alors que les thérapeutiques les plus efficaces sont logiquement utilisées à la phase adjuvante pour guérir le maximum de patientes. Cette exposition en adjuvant exerce une pression de sélection importante qui voit récidiver des tumeurs résistantes, plus agressives et théoriquement de moins bon pronostic. Malgré cela, la maladie métastatique peut être chronicisée par nos thérapeutiques et le contrôle de la maladie métastatique ne cesse d’être amélioré [1]. P. Greenberg, en analysant des patientes traitées dans les années 1990 par des protocoles à base d’anthracycline, avait mis en évidence des survies prolongées au-delà de dix ans pour plus de 10 % des patientes présentant une réponse complète avec la première ligne de chimiothérapie [2]. Aujourd’hui, cette proportion est considérablement augmentée et il est parfaitement justifié de proposer aux patientes des lignes itératives de traitements avec espoir d’efficacité. Les armes à notre disposition pour contrôler cette maladie métastatique combinent les traitements hormonaux, les chimiothérapies et les nouvelles thérapeutiques ciblées.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Giordano SH, Buzdar AU, Smith TL et al. (2004) Is breast cancer survival improving? Cancer 100: 44–52

    Article  PubMed  Google Scholar 

  2. Greenberg PA, Hortobagyi GN, Smith TL et al. (1996) Long-term followup of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197–2205

    PubMed  CAS  Google Scholar 

  3. Bonneterre J, Thurlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748–3757

    PubMed  CAS  Google Scholar 

  4. Mouridsen H, Gershanovich M, Sun Y et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606

    PubMed  CAS  Google Scholar 

  5. Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758–3767

    PubMed  CAS  Google Scholar 

  6. Klijn JG, Beex LV, Mauriac L et al. (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92: 903–911

    Article  PubMed  CAS  Google Scholar 

  7. Klijn JG, Blamey RW, Boccardo F et al. (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19: 343–353

    PubMed  CAS  Google Scholar 

  8. Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439–3460

    PubMed  CAS  Google Scholar 

  9. Pivot X, Asmar L, Buzdar AU et al. (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82: 529–534

    Article  PubMed  CAS  Google Scholar 

  10. Pivot X, Asmar L, Hortobagyi GN (1999) The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). Int J Oncol 15: 381–386

    PubMed  CAS  Google Scholar 

  11. Paridaens R, Biganzoli L, Bruning P et al. (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18: 724–733

    PubMed  CAS  Google Scholar 

  12. Chan S, Friedrichs K, Noel D et al. (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354

    PubMed  CAS  Google Scholar 

  13. Bontenbal M, Creemers GJ, Braun HJ et al. (2005) Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23: 7081–7088

    Article  PubMed  CAS  Google Scholar 

  14. Jassem J, Pienkowski T, Pluzanska A et al. (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707–1715

    PubMed  CAS  Google Scholar 

  15. Fumoleau P, Largillier R, Clippe C et al. (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 40: 536–542

    Article  PubMed  CAS  Google Scholar 

  16. O’Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823

    Article  PubMed  Google Scholar 

  17. Dufresne A, Pivot X, Tournigand C et al. (2008) Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 107: 275–279

    Article  PubMed  CAS  Google Scholar 

  18. Pivot XB, Li RK, Thomas ES et al. (2009) Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptorhuman epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cancer 45: 2940–2946

    Article  PubMed  CAS  Google Scholar 

  19. Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274

    Article  PubMed  CAS  Google Scholar 

  20. Wardley AM, Pivot X, Morales-Vasquez F et al. (2010) Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer. J Clin Oncol 28: 976–983

    Article  PubMed  CAS  Google Scholar 

  21. von Minckwitz G, du Bois A, Schmidt M et al. (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 27: 1999–2006

    Article  Google Scholar 

  22. Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743

    Article  PubMed  CAS  Google Scholar 

  23. Kaufman B, Mackey JR, Clemens MR et al. (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529–5537

    Article  PubMed  CAS  Google Scholar 

  24. Johnston S, Pippen J, Jr., Pivot X et al. (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538–5546

    Article  PubMed  CAS  Google Scholar 

  25. Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676

    Article  PubMed  CAS  Google Scholar 

  26. Miller KD (2003) E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3(6): 421–422

    Article  PubMed  CAS  Google Scholar 

  27. Gray R, Bhattacharya S, Bowden C et al. (2009) Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27: 4966–4972

    Article  PubMed  CAS  Google Scholar 

  28. Marty M, Pivot X (2008) The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with antiangiogenic agents, focusing on bevacizumab. Eur J Cancer 44: 912–920

    Article  PubMed  CAS  Google Scholar 

  29. Chan A, Miles DW, Pivot X (2010) Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 21: 2305–2315

    Article  PubMed  CAS  Google Scholar 

  30. Barrios CH, Liu MC, Lee SC et al. (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121: 121–131

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie, Hôpital Jean Minjoz, 3, boulevard Alexandre-Flemming, 25030, Besançn

    C. Villanueva, F. Bazan, L. Chaigneau, L. Cals, V. Sylvestre & X. Pivot

Authors
  1. C. Villanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Bazan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Chaigneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Cals
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Sylvestre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X. Pivot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Villanueva, C., Bazan, F., Chaigneau, L., Cals, L., Sylvestre, V., Pivot, X. (2011). Traitements systémiques des cancers du sein métastatiques. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_13

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation